公开(公告)号：US07202044B2

公开(公告)日：2007-04-10

申请号：US10476976

申请日：2002-05-08

申请人： Norbert Lamping ,  Hans-Dieter Zucht ,  Harmut Selle ,  Michael Jürgens ,  Gabriele Heine ,  Rüdiger Hess

发明人： Norbert Lamping ,  Hans-Dieter Zucht ,  Harmut Selle ,  Michael Jürgens ,  Gabriele Heine ,  Rüdiger Hess

IPC分类号： G01N33/53 ,  G01N33/567 ,  G01N33/536 ,  A61K38/28 ,  C07K5/00 ,  C07K14/00

CPC分类号： C07K14/52 ,  A61K38/00 ,  G01N33/6896 ,  G01N2500/00 ,  G01N2800/2814

摘要： The invention relates to defined peptides and the quantitative determination thereof in body fluids of patients suffering from progredient chronic dementia, in relation to the concentration of said peptides in a control group. The inventive peptides come from a protein precursor having the corresponding gene, are processed in a specific manner, and are optionally post-translationally modified, especially phosphorylized. An increase in the concentrations of these peptides or the corresponding non-processed protein indicates progredient chronic dementia. Progredient chronic dementia is detected by identifying the peptides and/or the protein individually or in combinations. The invention also relates to the use of said peptides for controlling the course of progredient chronic dementia and for the prognosis of progredient chronic dementia, especially for complementing or replacing mini-mental scores, and for developing therapeutic agents to combat progredient chronic dementia such as Alzheimer's disease.

摘要翻译： 本发明涉及定义的肽及其在患有慢性痴呆症的患者的体液中的定量测定，与所述肽在对照组中的浓度有关。 本发明的肽来自具有相应基因的蛋白质前体，以特定方式加工，并且任选地经翻译后修饰，特别是磷酸化。 这些肽或相应的未加工蛋白质的浓度的增加表示慢性痴呆。 通过单独或组合地鉴定肽和/或蛋白质来检测慢性痴呆。 本发明还涉及所述肽用于控制慢性痴呆进展过程以及慢性痴呆进展的预后，特别是用于补充或替代迷你精神分数，以及用于开发治疗剂以对抗慢性痴呆，如阿尔茨海默病 疾病。